Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676997 | 1.00 | SLC6A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10964540 | 0.99 | ALDH1A1 (1.00) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL9524452 | 0.93 | SLC6A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL9524447 | 0.93 | SLC6A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9528572 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10965807 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL9528575 | 0.92 | ALDH1A1 (0.87) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL10968322 | 0.91 | ALDH1A1 (0.86) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8820149 | 0.91 | SLC6A1 (0.83) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8820154 | 0.91 | SLC6A1 (0.83) | SLC6A1ALDH1A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912091-B1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-12-19 | — | — | EP | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| EP-0912091-A4 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| EP-1142584-A1 | COMPOSITIONS FOR TREATING FREQUENT URINATION AND URINARY INCONTINENCE | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | claimed |
| US-6121290-A | TREATING COUGH BY ADMINISTERING A COMPOUND THAT INHIBITS GABA (GAMMA-AMINO-BUTYRIC ACID) UPTAKE, SUCH AS GUVACINE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-09-19 | — | — | US | claimed |
| JP-2000511538-A | — | — | 2000-09-05 | — | — | JP | claimed |
| EP-0912091-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1997043902-A1 | USE OF GABA UPTAKE INHIBITORS AS ANTI-TUSSIVE AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-11-27 | — | — | WO | claimed |
| EP-0066456-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-24 | — | — | EP | claimed |
| US-4383999-A | GAMMA-AMINOBUTYRIC ACID SEDATIVES, ANALGESTICS, ANTIEPILEPTIC, MUSCULAR AND PSYCHOLOGICAL DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-17 | — | — | US | claimed |
| EP-0066456-A1 | N-substituted azaheterocyclic carboxylic acids and their esters | SMITHKLINE BECKMAN CORPORATION (US) | 1982-12-08 | — | — | EP | claimed |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | IMMEDICA PHARMA US INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025051360-A1 | TRKB-T1 AGONIST FOR THE TREATMENT OF ABSENCE SEIZURE AND/OR COMORBIDITIES | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2025-03-13 | — | — | WO | disclosed |
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | MARINUS PHARMACEUTICALS, INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | MARINUS PHARMACEUTICALS, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-0221572-A2 | N-substituted 3-piperidine-or 3-pyridine-carboxylic acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| WO-1987000171-A1 | AMINO ACID DERIVATIVES | NOVO INDUSTRI A/S (DK) | 1987-01-15 | — | — | WO | disclosed |
| EP-0066456-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4383999-A | GAMMA-AMINOBUTYRIC ACID SEDATIVES, ANALGESTICS, ANTIEPILEPTIC, MUSCULAR AND PSYCHOLOGICAL DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-17 | — | — | US | disclosed |
| EP-0066456-A1 | N-substituted azaheterocyclic carboxylic acids and their esters | SMITHKLINE BECKMAN CORPORATION (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246026-B2 | Ganaxolone for use in treatment of status epilepticus | CYP21A2, CYP17A1, HSD17B11 | SLC6A1 276/4885ALDH1A1 2021/4885LMNA 3480/4885 |
| US-20260021111-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP4A11, CYP21A2, CYP17A1 | SLC6A1 253/4885ALDH1A1 3830/4885LMNA 2794/4885 |
| US-20230405021-A1 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS | CYP21A2, CYP17A1, HSD17B11 | SLC6A1 276/4885ALDH1A1 2021/4885LMNA 3480/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | SLC6A1 443/4885ALDH1A1 735/4885LMNA 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.